ABOS News and Press, Acumen Pharmaceuticals Inc.

NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc.  (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), ...

- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo ® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease - Option exercise puts Acumen’s Enhanced Brain Delivery (EBD!...

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen’s option under its license agreement with JCR Pharmaceuticals EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a ther...

2026-05-20 07:45:03 ET ... Read the full article on Seeking Alpha For further details see: Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet

2026-05-14 14:20:43 ET Acumen Pharmaceuticals, Inc. (ABOS) Bank of America Global Healthcare Conference 2026 May 14, 2026 11:55 AM EDT... Read the full article on Seeking Alpha For further details see: Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global He...

2026-05-12 12:40:49 ET Image source: The Motley Fool. May 12, 2026, 8:00 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-12 11:31:52 ET More on Acumen Pharmaceuticals Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EB...

2026-05-12 11:30:49 ET Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript

2026-05-12 07:14:07 ET More on Acumen Pharmaceuticals Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding Seeking Alpha’s Quant Rating on Ac...

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s EBD TM (enhanced brain delivery) program targeted for mid-2027 Cash, ca...